PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :		(11) International Publication Number: WO 94/060	
G06F 15/42	A1	(43) International Publication Date: 17 March 1994 (17.03.	
(21) International Application Number: PCT/SE (22) International Filing Date: 27 August 1993	BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,		
(30) Priority data: 9202460-3 27 August 1992 (27.08.92	2)	Published With international search report. In English translation (filed in Swedish).	
(71)(72) Applicants and Inventors: SILLÉN, Rudolf, [SE/SE]; Åvägen 14, S-372 51 Ronneby (SE BERG, Göran [SE/SE]; Källarbäcksvägen 21, Uppsala (SE).). WE	S-	
(74) Agent: AWAPATENT AB; Box 5117, S-200 1 (SE).	7 Malı	nö	

(54) Title: METHOD AND APPARATUS FOR CONTROLLED INDIVIDUALIZED MEDICATION

(57) Abstract

A method and a device for giving patients individualised, situation-dependent medication advice are disclosed. Preferably, the invention is implemented in portable computers. The method is founded on knowledge-based computer technology and comprises a reminder function (1), a recording and storage function (2, 3), as well as a function for inductive data analysis (4) and rule generation. When the knowledge-based system (6) finds that a medicine should be taken, the computer emits a signal providing information on the type of medicine and the dose. The patient records the intake of medicine as well as his current state of health. This information is stored in a database together with the point of time. Inductive data analysis is used to spot the relationship between various events and symptoms as well as establish medication rules. These rules are refined upon as new information is recorded in the database, and are automatically adapted to changes in the patient's state of health.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	iE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic	RU	Russian Federation
CF	Central African Republic		of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
СМ	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	AU	Ukraine
DE	Germany	MG	Madagascar	US	United States of America
DK	Denmark	ML	Mali	UZ	Uzbekistan
ES	Spain	MN	Mongolia	VN	Vict Nam
FI	Finland				

5

20

30

1

Method and apparatus for controlled individualized medication.

This invention relates to a method for controlled individualised medication.

Many chronic diseases in man require the administration of various substances in order to counteract the disease and/or to keep down its symptoms. Medication often includes several different pharmaceutical preparations, each having its specific properties, duration of action, 10 and so forth. Dosage and time intervals between administrations depend on the status of the disease, patientspecific factors, such as inheritance, age, weight, general state of health as well as diet and physical activities. As a result, medication is a fairly complicated 15 task to perform. In practice, this will manifest itself as variations in the patient's state of health. In the case of some diseases, such as Parkinson's disease, the symptoms may in a single day vary from making the patient incapacitated for work (rigidity, tremor, etc.) to leaving the patient almost untroubled.

There are several different methods used for providing recommendations as to the dosage and the time intervals between administrations. These recommendations are often founded on the adjustment of an initial concept based on pharmacokinetic information on the various preparations. The adjustments are made on the basis of recordations of the patient's condition on various occasions. This information is interpreted by specialists, and used for adjusting the dosage and the time intervals.

However, the methods currently used do not yield desirable results, the reason being that the pharmacokinetic effects of the preparations are not absolutely clear. The way the preparations move through the body is affected by interactions with other preparations, enzymes and so forth, during the absorption and the distribution phase as well as during the metabolism and the secretion phase. Thus, the actual concentration of a preparation in the

biophase, the duration of action and the effect cannot be predicted statistically using monotonic models. Another reason is that the evaluation of the patient's data is a complex operation since it involves many dependent vari-5 ables and since it further is difficult to lay down analytical models.

It is likely that the state of health of certain groups of patients can be drastically improved by optimum, individualised and situation-dependent medication. This 10 would result in enhanced quality of life, as well as fewer sickness pensioners.

GB 2,218,831 teaches an apparatus for helping people suffering from chronic diseases, such as diabetes, to determine medication doses and keep a suitable diet, 15 thereby to improve their state of health. This apparatus has a key pad for entering data on the blood glucose levels as well as the physical activity of the patient, a memory where e.g. data on the prescribed dosage are stored, a program for computing suitable doses of insulin 20 on the basis of inputted data as well as data stored in the memory, and a display for showing the doses of insulin computed.

Similar apparatus are described in US Patent 5,019,974 and EP Patent Application 0 128 054.

25

35

These prior-art apparatus are all based on there being a known relationship between a condition of the patient, such as the blood glucose level, and the wellbeing of the patient, and on the medication having a known effect on the patient. Thus, one may establish fixed medi-30 cation rules valid for comparatively long periods of time.

However, in the case of other chronical diseases, such as Parkinson's disease, epilepsy and abnormal blood pressures, there does not exist any single actual value or condition of the patient that can be measured and correlated with the well-being of the patient. For these diseases, medication generally includes several medicines, whose precise interactions and effects on the patient are

3

not fully known. In addition, the health condition of the patient is affected by a plurality of external factors. Thus, it is impossible to establish fixed medication rules valid for long periods of time, and the prior-art apparatus therefore cannot be used for controlled individualised medication in the treatment of more complicated diseases.

The object of the present invention is to provide a method and a device for controlled, individualised medication in the treatment of complicated diseases whose mechanisms are not fully known, thereby to improve the patient's state of health.

This object is attained by a method and a device having the distinctive features recited in appended claims 1 and 9, respectively. Other features of the invention are stated in the appended subclaims.

15

The invention has the great advantage of automatically drawing conclusions from the inputted data as to what activities, what external factors and what medication will result in a satisfactory state of health for the patient.

20 On the basis of these conclusions, rules are established regarding when and in what doses the different medicines are to be taken. The thus-established rules are not fixed, but are continuously refined upon with the aid of data recorded by the patient. Thus, the invention gradually

25 "learns" what is needed for the well-being of the patient. Further, the rules are automatically adapted to changes in the patient without the device having to be reprogrammed.

The invention will be described in more detail below with reference to the accompanying drawing, which schema30 tically illustrates the structure of a device in accordance with the invention.

The aim of the invention is to give the patients controlled, individualised and situation-dependent medication advice, thereby to enhance the patient's sense of well-being to an optimum extent. The inventive method is adaptive, i.e the basic rules for the advice are altered if the relevant factors affecting the patient are changed.

4

Conveniently, the invention is implemented in portable "wallet-size" computers.

As appears from the drawing, the method is founded on a knowledge-based computer system or expert system 6 having a reminder function 1, a recording and storage function 2, 3, as well as a function 4 for inductive rule generation.

When the system is operating, the reminder function
1 is normally activated. The computer emits a signal when
10 a pharmaceutical preparation is to be taken (or some other
activity is to be performed), and advises on the type of
preparation to be taken as well as the dosage. In the
recording function 2 of the system, the patient confirms
that the medicine has been taken, and then indicates his
15 current state of health by responding to questions put to
him by the computer. In addition, the patient separately
records other relevant events, such as awakening, intake
of food, exercise and stress, when these occur, and also
indicates his current state of health.

These data are stored in a database 3 together with the point of time at issue. Optionally, some information may be automatically retrieved by sensors.

The information, which constitutes a situation database 3, is used for determining relevant relations in time between various events and to generate examples distinguishing the different symptoms that are to be controlled. The examples consist of values for the attributes (affecting factors) that are relevant, as well as the associated symptom value (conclusion). The attributes used for each preparation are, among others, "latest dosage", "time from intake", and "remaining duration of action".

30

35

Collections of examples are automatically created every day for each group of symptoms. These collections are accumulated in a "rolling" database, preferably including the values from the last 20 days. The examples are then used in each group of symptoms for spotting, with the aid of prior-art inductive data analysis 4, the rela-

5

tionships that exist, and drafting rules for predicting the symptoms.

Inductive data analysis and rule generation are described in, inter alia, the following publications:

5 Quinlan, JR (1979), Discovering Rules by Induction from Large Collections of Examples, Introductory Readings in Expert Systems (D. Michie), pp 33-46, London; Gordon and Breach 1979. Quinlan, JR (1983), Learning from Noisy Data, Proceedings of the International Machine Learning Work
10 shop, University of Illinois, pp 58-64, 1986.

The prediction rules are generated in the form of decision trees and/or so-called conditional rules of the type:

IF X1<0.12 AND Z3="protein B" AND Z1>0.34 AND Z2=2 THEN 15 RIGIDITY = "excessive agility".

The rules are validated by being tested at 5 against borderline cases drawn up on long-term experience. Approved rules are transferred to the knowledge base in an expert system 6 in known manner. The expert system may be a conventional rule-based system or be based on fuzzy logic. Then, the expert system is able to predict the state of health of the patient by part predictions of the various symptoms in a specific situation.

When in use, the expert system is automatically called at 8 at regular time intervals, preferably every fifth minute. When called, the system is consulted with respect to the current values from the situation database. In consultation, time data are displaced forwards, preferably by a time factor corresponding to the time elapsing from the intake of a preparation to the attainment of its biophase. This makes it possible for the system to signal before any undesirable effects appear (early warning system). The consultation is performed in known manner via "backward chaining", i.e. starting from a desirable

conclusion (state of health). Desirable conclusions can be predetermined for every group of symptoms.

The expert system operates in real time and can, in each specific situation, find in good time the prerequi-5 sites and conditions that have to be met to achieve the desired state of health. If this state cannot be achieved in a specific situation (e.g. because the patient has forgotten to act on previous advice), the system looks for the prerequisites for attaining the "second-best" state of 10 health. Induction of rules and updating of the knowledge base are performed automatically by the system, conveniently once every twenty-fourth hour. Because the system learns to detect patterns by induction of real situations, the system can provide individualised medication advice without having access to explicit causal connections and pharmacological data, the prerequisite being that the attributes used directly or indirectly represent patterns that can be classified. According to the invention, the patient records the point of time when he takes the various preparations, the dosage as well as his current state of health. These data are used for generating, by inductive data analysis, prediction rules that are used for providing advice on the point of time and the dosage.

20

30

35

For each preparation, one starts from a patient-specific longest nominal duration of action. In the examples, the remaining duration of action as well as the dosage of the latest and the latest-but-one intake are determined. Also other relevant factors, such as the intake of food, state of stress and related time, are also included in the examples.

The prediction rules generated by prior-art inductive data analysis are called at predetermined intervals, and a time delay is then introduced, which preferably corresponds to the time elapsing, in the case of the different preparations, from the intake to the attainment of the biophase. The prediction rules are called by backward chain, primarily in order to satisfy the current situation

7

to attain the desired state of health. If any of the conditions that can be influenced is not satisfied, e.g. the dosage of a preparation, the system will recommend that this be done.

5 A mode of operation of the invention, intended for controlled, individualised adaptive medication in the treatment of Parkinson's disease, will be described below. In Parkinson's disease, the body cannot produce sufficient amounts of a neurotransmitter in the brain called dopamine, which results in limitations of movement, muscular cramp and tremor. This state can be counteracted by the supply of various preparations, such as L-dopa, which are converted to dopamine or the substance bromokriptin. In order to master undesirable side-effects, such as effects 15 on the blood pressure, these preparations generally have to be combined with other medicines. Thus, medication frequently involves at least three different preparations, each having a specific dosage and a specific time interval between administrations. Owing to the interactions 20 taking place, the time intervals and the doses have to be adapted to one another. Also external factors, such as the intake of food, exercise and state of stress, affect the action of the preparations. As a result, patients that have been ill for a long time, and thus have had plenty of time to find which medication suits them best, are seldom perfectly untroubled for a whole day. Frequently, there are two or more periods during the day in which they experience considerable discomfort in the form of tremor, rigidity and "dullness of mind". Too low a dosage typically results in tremor, rigidity and muscular cramp. Discomfort caused by overdosage is not less common, manifesting itself in the form of uncontrolled excessive agility, among other things. The reminder function indicates when the preparations, such as Pravidel, Sinemet, Inderal, Madopark, and Eldepryl, are to be taken, and further provides recommendations as to the intake of liquid, food and rest.

8

The recording function includes compulsory input of the state of health expressed as degrees of the attributes "Rigidity", "Agility", "Tremor" and "Dullness of Mind". Recordation is also performed when other important events take place, such as "awakening", "falling asleep", "eating" and "drinking". In recordation, the time is indicated in minutes from the awakening.

When generating examples, the times elapsing from the intake of the various preparations and events to the pre10 sent time are determined. Two times are preferably determined for each preparation, namely the time that has elapsed from the latest-but-one intake and the time that has elapsed from the latest intake.

A nominal duration of action from the intake is used 15 for the various preparations. When the individual duration of action is known, this is indicated.

At the end of each day, a collection of examples with attribute values determined as above is created.

The recorded state of health is indicated as conclusion for each example.

A collection of examples is thus made for each of the indicated states of health, i.e. one collection of examples with the conclusion related to "Rigidity", one collection related to "Tremor", and one collection related to "Dullness of Mind". Then, rules are induced from the collections of examples, and the rules are validated by comparing their threshold values with indicated maximum and minimum limits as to dosage and time.

If a rule falls outside these limits, the indicated 30 limit values are used.

25

Thereafter, the rules are transferred to the know-ledge base in a deductive expert system.

The generation of examples, the induction and the transfer to the database are initiated at the end of each day and are perfectly automatic.

PCT/SE93/00708 WO 94/06088

9

When using the system, the reminder function is activated when the patient starts the computer upon awakening.

The reminder function calls the expert system at intervals of preferably about 5 min, and the expert system 5 is thus consulted with respect to the data recorded. In consultation, an advance time corresponding to the average time elapsing from the intake of a preparation to its commenced action, is added to the real time. Preferably, the advance time is 30 min. Consequently, the system will be able to issue reminders in good time.

15

10

20

25

30

10

CLAIMS

1. A method for controlled, individualised medication, characterised by

recording, every time the patient takes his medicine, the type of medicine, the dose and the point of time in a database,

recording information on the patient's state of health 10 on recurrent occasions in the database,

analysing the information recorded in the database by means of inductive data analysis in order to establish medication rules on the basis of detected relationships between the patient's intake of medicine and his state of health.

comparing the established medication rules with predetermined medication conditions for approval,

using the approved rules for continuously deciding whether medication is to be performed and, if so, deciding the type of medicine and the dose, and


repeating the analysis of the database for continuously optimising the medication rules with the aid of new information recorded in the database and for adapting the rules to changes in the patient's state of health.

- 25 2. A method as set forth in claim 1, character is ed by the medication comprising the administration of at least two different medicines.
 - 3. A method as set forth in claim 1 or 2, c h a r a c t e r i s e d by also recording information on the patient's intake of food and his activities in the database, and taking this information into consideration when establishing the medication rules.
- A method as set forth in any one of the preceding claims, c h a r a c t e r i s e d by always recording
 the patient's state of health when recording his intake of medicine.

11

5. A method as set forth in any one of the preceding claims, c h a r a c t e r i s e d by calculating the relations in time between various external events recorded and the state of health recorded.

- 6. A method as set forth in any one of the preceding claims, characterised by allotting a duration of action to each medicine, and continuously calculating the remaining duration of action of the medicine taken.
- 7. A method as set forth in any one of the preceding claims, c h a r a c t e r i s e d by using the dose and the remaining duration of action as attributes in the inductive data analysis.
- 8. A method as set forth in any one of the preceding claims, characterised by being used in the treatment of Parkinson's disease.
 - 9. A device for controlled, individualised medication, characterised by means (2) for recording information on the intake of medicine and the pa-
- tient's state of health, a database (3) for storing this information, a program (4) for performing an inductive analysis of the information stored in the database and establishing medication rules on the basis of detected relationships between the intake of medicine and the
- patient's state of health, memory means (5) for storing predetermined medication conditions, means (5) for comparing the medication rules established by means of the program for performing inductive analysis and the predetermined medication conditions for approval of the medi-
- cation rules, an expert system (6) where the approved rules are used for deciding whether medication is to be performed and, if so, which type of medicine and what dose should be given, means (7) for activating the program for inductive analysis at given points of time, and means (8)
- 35 for polling the expert system at given points of time.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 93/00708

A. CLASSIFICATION OF SUBJECT MATTER IPC5: G06F 15/42 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC5: G06F Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Category* Citation of document, with indication, where appropriate, of the relevant passages EP, A2, 0303930 (SYNTHES AG), 22 February 1989 1-9 A (22.02.89)A GB, A, 2218831 (MARK JOHN NEWLAND), 1-9 22 November 1989 (22.11.89) US, A, 5019974 (ANDREAS G.F. BECKERS), 28 May A 1-9 1991 (28.05.91) A EP, A1, 0128054 (SIMATEC S.A.R.L.), 1-9 12 December 1984 (12.12.84) Further documents are listed in the continuation of Box C. See patent family annex. later document published after the international filing date or priority Special categories of cited documents: date and not in conflict with the application but cited to understand "A" document defining the general state of the art which is not considered the principle or theory underlying the invention to be of particular relevance erlier document but published on or after the international filing date "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive document which may throw doubts on priority claim(s) or which is step when the document is taken alone cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed being obvious to a person skilled in the art "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search **01** -12- **1993** 23 November 1993 Name and mailing address of the ISA/ Authorized officer Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Jan Silfverling Facsimile No. +46 8 666 02 86 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/10/93

International application No. PCT/SE 93/00708

	locument arch report	Publication date		ent family ember(s)	Publication date
EP-A2-	0303930	22/02/89	US-A-	4839822	13/06/89
GB-A-	2218831	22/11/89	NONE		
US-A-	5019974	28/05/91	EP-A-	0290683	17/11/88
EP-A1-	0128054	12/12/84	SE-T3- CA-A- FR-A- JP-A- US-A-	0128054 1210867 2544525 60051970 4686624	02/09/86 19/10/84 23/03/85 11/08/87

Form PCT/ISA/210 (patent family annex) (July 1992)